Alyson Blakstad, OD
Corneal and Contact Management · Minnetonka, MNNPI 1427043660
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Sight Sciences, Inc. at 28.8% of the total. Reporting peaked in 2021 at $191 and has fallen 91.7% since, to $16 in 2025.
Across 12 payments — averaging $43.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$149
- Glaukos Corporation$144
- Synergeyes, Inc.$84
- Oyster Point Pharma, Inc.$55
- Novartis$39
- Tarsus Pharmaceuticals, Inc.$31
- plus $16 from 1 others
What the payments were for
- Food & beverage$518100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 1 | $149 |
| Glaukos Corporation | 1 | $144 |
| Synergeyes, Inc. | 2 | $84 |
| Oyster Point Pharma, Inc. | 3 | $55 |
| Novartis | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 2 | $31 |
| Coopervision Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare SmartLid$149
- TEARCARE(TM) (2.2) SYSTEM KIT$149
- KXL System$144
- Photrexa$144
How this compares
$518 in reported general payments places this provider in the 55th percentile of 30 corneal and contact management providers in Minnesota.
See all corneal and contact management providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 88 | $114,147 |
| Cyclosporine | 50 | $41,790 |
| XiidraLifitegrast | 21 | $30,212 |
| LumiganBimatoprost | 39 | $19,148 |
| VyzultaLatanoprostene Bunod | 30 | $15,269 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $11,606 |
| RhopressaNetarsudil Mesylate | 14 | $6,098 |
| Fluorometholone | 69 | $5,324 |
| Latanoprost | 251 | $4,990 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $4,277 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $4,203 |
| Brimonidine Tartrate | 85 | $3,442 |
| Prednisolone Acetate | 58 | $2,974 |
| Travoprost | 17 | $2,787 |
| Timolol Maleate | 189 | $2,515 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Minnetonka
- Ahmad FahmyMinneapolis$222K
- Scott HauswirthBloomington$73K
- Mark BuboltzBloomington$6K
- Tina McCartyFridley$3K
- Thomas EltonEdina$2K
- Alicia AlvaradoFridley$2K
- Johnna HobbsBloomington$2K
- Michael NovakWillmar$2K
- Robert DingaOakdale$962
- Michael NagelWillmar$767
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.